Showing 1 - 7 results of 7 for search 'Alain Vergnenegre', query time: 0.03s Refine Results
  1. 1
    Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

    Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 stu... by Christos Chouaid, Hervé Le, Chrystelle Locher, Cecile Dujon, Pascal Thomas, Jean Bernard Auliac, Isabelle Monnet, Alain Vergnenegre

    Published 2012-07-01
    Get full text
    Article
  2. 2
    Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.

    Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers. by Matthieu Dusselier, Elise Deluche, Nellie Delacourt, Julia Ballouhey, Thomas Egenod, Boris Melloni, Charlotte Vergnenègre, Rémi Veillon, Alain Vergnenègre

    Published 2019-01-01
    Get full text
    Article
  3. 3
    Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

    Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04) by Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, the GFPC Team

    Published 2020-01-01
    Get full text
    Article
  4. 4
    Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

    Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung c... by Isabelle Monnet, Alain Vergnenègre, Gilles Robinet, Henri Berard, Regine Lamy, Lionel Falchero, Sabine Vieillot, Roland Schott, Charles Ricordel, Stephane Chouabe, Pascal Thomas, Radj Gervais, Anne Madroszyk, Samir Abdiche, Anne Marie Chiappa, Laurent Greillier, Chantal Decroisette, Jean Bernard. Auliac, Christos Chouaïd

    Published 2021-04-01
    Get full text
    Article
  5. 5
    Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

    Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients by Jacques Cadranel, Alexis B. Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse

    Published 2018-02-01
    Get full text
    Article
  6. 6
    Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital

    Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hos... by Sandra Pinet, Stéphanie Durand, Alexandre Perani, Léa Darnaud, Fifame Amadjikpe, Mathieu Yon, Tiffany Darbas, Alain Vergnenegre, Thomas Egenod, Yannick Simonneau, Valérie Le Brun-Ly, Julia Pestre, Laurence Venat, Frédéric Thuillier, Alain Chaunavel, Alain Chaunavel, Mathilde Duchesne, Mathilde Duchesne, Véronique Fermeaux, Anne Guyot, Sylvain Lacorre, Barbara Bessette, Fabrice Lalloué, Karine Durand, Karine Durand, Elise Deluche, Elise Deluche

    Published 2023-02-01
    Get full text
    Article
  7. 7
    Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

    Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer by Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria, Rafael Rosell

    Published 2023-03-01
    Get full text
    Article

Search Tools: